Anzeige
Mehr »
Dienstag, 08.07.2025 - Börsentäglich über 12.000 News
750-Millionen-Euro-Finanzier verstärkt Forge - Sichtbares Gold befeuert Exploration
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40D0L | ISIN: SE0022060521 | Ticker-Symbol: IV61
Tradegate
08.07.25 | 16:36
8,046 Euro
+6,99 % +0,526
1-Jahres-Chart
KINNEVIK AB B Chart 1 Jahr
5-Tage-Chart
KINNEVIK AB B 5-Tage-Chart
RealtimeGeldBriefZeit
8,1488,22418:12
8,1488,22418:12
GlobeNewswire (Europe)
37 Leser
Artikel bewerten:
(0)

Kinnevik AB: Kinnevik's Interim Report 1 January - 30 June 2025

"Kinnevik concludes a solid second quarter with strong growth and continued margin improvements in our core companies. We also continue to selectively add exciting companies to our portfolio and in the quarter we led a funding round in Tandem Health. We are proud to partner with a Swedish company at the intersection of healthcare, SaaS and AI, as it pioneers the next generation of healthcare infrastructure in Europe."

Georgi Ganev, CEO of Kinnevik

Key Events

  • During the first half of 2025, our core companies grew revenues by more than 35 percent on average and improved EBITDA margins by 4 percentage points year-on-year
  • TravelPerk passed USD 275m in annualized revenues, up from USD 200m at the beginning of the year through continued strong organic growth and the acquisition of Yokoy
  • Enveda's leading drug candidate successfully completed Phase 1a clinical trials, a validation of the company's AI-driven drug discovery platform
  • We led a EUR 40m funding round with an investment of EUR 30m in Tandem Health, a Swedish healthcare infrastructure company pioneering a medical AI scribe designed to reduce administrative workloads for healthcare providers. The company's vision is to build the European operating system for clinical workflows

Investment Activities

  • SEK 860m invested in the quarter, bringing investments during the first half of 2025 to SEK 1,660m (SEK 1,293m net of divestments) - indicative of current target investment pace
  • Invested SEK 333m in Tandem Health as lead investor in a EUR 40m funding round, adding a larger investment to our selective early-stage portfolio additions during the first half of 2025
  • Invested SEK 335m in a new techbio company, to be announced during the second half of 2025

Financial Position

  • Net Asset Value of SEK 36.8bn (SEK 133 per share), up 0.6bn or 2 percent in the quarter (up 4 percent in constant currencies)
  • Private portfolio up 3 percent (up 5 percent in constant currencies), driven by solid operational performance, muted multiple expansion, and currency headwinds
  • Net cash of SEK 9.6bn at end of the second quarter, with limited follow-on investment needed in the portfolio

A conference call will be held today at 10.00 CET to present the results. The conference call will be held in English. Those who wish to participate and ask questions during the conference call are welcome to register via the link below. Participants will receive dial-in numbers and confirmation code upon registration. Please make sure to register and dial in a few minutes before the call begins.

  • Link to the listen-only webcast: https://edge.media-server.com/mmc/p/5wzbrchy/
  • Link to the conference call for participants: https://register-conf.media-server.com/register/BI58ae497b395743bd9d15743aac608abb

This information is information that Kinnevik AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (596/2014) and the Securities Markets Act (Sw. lagen (2007:528) om värdepappersmarknaden). The information was submitted for publication, through the agency of the contact person set out below, at 2025-07-08 08:00 CEST.

For further information, visit www.kinnevik.com or contact:

Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Email press@kinnevik.com

Kinnevik is a leading growth investor on a mission to redefine industries and create remarkable growth companies. We are an active owner and operational partner, providing patient capital to challenger technology-enabled businesses in Europe and the US. Our passionate founders are building tomorrow's leaders within healthcare, software and climate, making everyday life easier and better for people around the world. We invest at all stages of a company's growth journey, always determined to create long-term value. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik's shares are listed on Nasdaq Stockholm's list for large cap companies under the ticker codes KINV A and KINV B.

© 2025 GlobeNewswire (Europe)
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.